Dissociation in Esketamine Therapy: Clinical Impact and Practice in Israel
A 2021–2025 Israeli study finds dissociation during esketamine treatment for depression is common but does not hinder antidepressant efficacy—even in patients with trauma-related comorbidities.
Dissociation Does Not Impair Esketamine's Antidepressant Efficacy
Recent findings from a 2021–2025 retrospective chart review at Lev Hasharon Mental Health Center in Israel demonstrate that dissociation, while common during esketamine therapy for treatment-resistant depression, does not diminish the antidepressant effects of the drug. The study, published on November 18, 2026 (OpenAlex W7235864368), analyzed outcomes in 51 adults undergoing intranasal esketamine treatment according to a structured induction and maintenance protocol. Dissociation was measured using the Dissociative Experiences Scale-II (DES-II) for baseline trait dissociation and the Peritraumatic Dissociative Experiences Questionnaire (PDEQ) for weekly session-related state dissociation. Despite higher trait dissociation being associated with greater baseline depressive severity (r = .28, p = .03), neither trait nor session-level dissociation were found to impede the pace or magnitude of improvement in depressive symptoms as measured by the QIDS-SR16.
Mechanisms: Trait and State Dissociation in Esketamine Therapy
Trait dissociation, reflecting a person's general tendency to dissociate, and state dissociation, referring to acute dissociative experiences during treatment sessions, were both assessed in this cohort. The study found a moderate correlation between trait and state dissociation (r = .310, p = .038), indicating that individuals with higher baseline dissociative tendencies were more likely to experience pronounced in-session dissociation. Notably, patients with trauma-related comorbidities—such as post-traumatic stress disorder (PTSD)—had elevated trait dissociation and higher initial depressive burden. However, this did not translate into poorer antidepressant response to esketamine. These results challenge the hypothesis that dissociation is either necessary for or detrimental to the therapeutic effects of esketamine, instead suggesting it is an epiphenomenon—an accompanying effect without causal influence on treatment outcomes.
Clinical and Policy Implications: Integration Support and Monitoring
The study’s findings have direct implications for clinical practice, safety monitoring, and policy development in esketamine and broader psychedelic-assisted therapies. While session-level dissociation showed a trend-level association with transient mood worsening at the following visit (p ≈ .06), this effect was short-lived and did not impact long-term antidepressant efficacy. This transient worsening mirrors patterns observed in other psychedelic-assisted therapies, such as those using psilocybin or MDMA, where acute psychological effects may temporarily exacerbate symptoms before improvement. The authors recommend brief, post-session integration support to address these short-term effects, a practical step that could be incorporated into standard protocols without significant resource burden. Importantly, the study provides evidence to inform regulatory guidance and insurance coverage decisions: dissociation, even when pronounced, should not be used as a criterion to exclude patients from esketamine therapy or to limit access.
- For clinicians: Monitoring dissociation remains important for patient comfort and safety, but its presence alone does not predict poor outcomes.
- For policymakers and payers: The data support continued coverage of esketamine for patients with trauma-related comorbidities, as they are not at increased risk of treatment failure due to dissociation.
- For researchers: The study highlights the need to further investigate the mechanisms by which acute subjective effects relate—or do not relate—to clinical benefit in psychedelic and dissociative therapies.
Risks, Limitations, and Unknowns
While dissociation during esketamine therapy does not appear to hinder antidepressant effects, it remains a complex and sometimes distressing experience for patients. The transient association with short-term mood worsening, although not statistically robust (p ≈ .06), suggests that some individuals may benefit from additional support immediately following sessions. The retrospective nature of the study and its single-site design in Israel may limit generalizability. Furthermore, the sample size (n = 51) restricts the ability to detect rare adverse events or subtle subgroup effects. Notably, the study did not systematically assess for long-term cognitive or functional impacts of repeated dissociation, an area that warrants further investigation. A non-obvious implication is that integration support, even when brief, could mitigate not only psychological discomfort but also potential dropout—an operational consideration for clinics seeking to optimize adherence and outcomes.
Looking Forward: Refining Practice and Research on Subjective Drug Effects
These findings contribute to a growing body of evidence suggesting that the acute subjective effects of esketamine and similar agents, such as dissociation, are not reliable predictors of therapeutic outcome. This challenges earlier assumptions drawn from both psychiatric and psychedelic medicine that the intensity of acute effects might correlate with benefit. Future research should focus on identifying which, if any, subjective experiences are mechanistically linked to clinical improvement, and whether tailored integration protocols can further enhance safety and efficacy. As esketamine and other psychedelic therapies expand globally, nuanced understanding of these phenomena will be critical for optimizing patient care and regulatory frameworks.
By Dr. Tamar Eliaz, MD, MSc, Clinical Psychiatrist and Research Fellow. How we research: This article is based on direct review of the primary study (OpenAlex W7235864368), institutional protocols, and regulatory guidance, and was reviewed by Dr. Eliaz on 2026-11-20.
Get tomorrow's briefing in your inbox
Policy, research, and regulatory signal — delivered on our publish cadence.